Similar articles for PMID: 12199976

Year	Number of Results
1931	1
1961	1
1987	1
1988	2
1990	1
1993	1
1994	1
1995	2
1997	8
1998	12
1999	16
2000	14
2001	8
2002	18
2003	16
2004	8
2005	6
2006	9
2007	4
2008	6
2009	3
2010	3
2011	5
2012	4
2013	4
2014	2
2018	1
2020	2
2024	0

1

[Does abciximab improve the prognosis of diabetics after percutaneous coronary intervention?].

Hernández García JM, Domínguez Franco A, Jiménez-Navarro MF, Alonso Briales JH, Curiel Balsera E, Gómez Doblas JJ, De Teresa Galván E. Hernández García JM, et al. Rev Esp Cardiol. 2002 Aug;55(8):810-5. Rev Esp Cardiol. 2002. PMID: 12199976 Free article. Spanish.

2

Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.

Kleiman NS, Lincoff AM, Kereiakes DJ, Miller DP, Aguirre FV, Anderson KM, Weisman HF, Califf RM, Topol EJ. Kleiman NS, et al. Circulation. 1998 May 19;97(19):1912-20. doi: 10.1161/01.cir.97.19.1912. Circulation. 1998. PMID: 9609084 Clinical Trial.

3

Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.

Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, Harrington RA, Topol EJ. Lincoff AM, et al. J Am Coll Cardiol. 1997 Jul;30(1):149-56. doi: 10.1016/s0735-1097(97)00110-1. J Am Coll Cardiol. 1997. PMID: 9207636 Free article. Clinical Trial.

4

Effect of abciximab on late adverse events in patients with diabetes mellitus undergoing stent implantation.

Velianou JL, Mathew V, Wilson SH, Barsness GW, Grill DE, Holmes DR Jr. Velianou JL, et al. Am J Cardiol. 2000 Nov 15;86(10):1063-8. doi: 10.1016/s0002-9149(00)01160-7. Am J Cardiol. 2000. PMID: 11074200

5

Long-term clinical benefits of a platelet glycoprotein IIb/IIIa receptor blocker, abciximab (ReoPro), in high-risk diabetic patients undergoing percutaneous coronary intervention.

Sim DS, Jeong MH, Kim W, Rhew JY, Yum JH, Kim JH, Cho JG, Ahn YK, Park JC, Ahn BH, Kim SH, Kang JC. Sim DS, et al. Korean J Intern Med. 2003 Sep;18(3):129-37. doi: 10.3904/kjim.2003.18.3.129. Korean J Intern Med. 2003. PMID: 14619381 Free PMC article. Clinical Trial.

6

Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.

Marso SP, Lincoff AM, Ellis SG, Bhatt DL, Tanguay JF, Kleiman NS, Hammoud T, Booth JE, Sapp SK, Topol EJ. Marso SP, et al. Circulation. 1999 Dec 21-28;100(25):2477-84. doi: 10.1161/01.cir.100.25.2477. Circulation. 1999. PMID: 10604884 Clinical Trial.

7

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.

Suleiman M, Gruberg L, Hammerman H, Aronson D, Halabi M, Goldberg A, Grenadier E, Boulus M, Markiewicz W, Beyar R. Suleiman M, et al. J Invasive Cardiol. 2003 Jun;15(6):319-23. J Invasive Cardiol. 2003. PMID: 12777670

8

Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.

Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schömig A; Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators. Mehilli J, et al. Circulation. 2004 Dec 14;110(24):3627-35. doi: 10.1161/01.CIR.0000148956.93631.4D. Epub 2004 Nov 7. Circulation. 2004. PMID: 15531766 Clinical Trial.

9

Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Bhatt DL, et al. J Am Coll Cardiol. 2000 Mar 15;35(4):922-8. doi: 10.1016/s0735-1097(99)00650-6. J Am Coll Cardiol. 2000. PMID: 10732889 Free article.

10

Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.

Haase KK, Mahrholdt H, Schröder S, Baumbach A, Oberhoff M, Herdeg C, Karsch KR. Haase KK, et al. Am Heart J. 1999 Feb;137(2):234-40. doi: 10.1053/hj.1999.v137.93038. Am Heart J. 1999. PMID: 9924156 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

154 results

Results by year